ARCHIVES

Perifosine, Sorafenib Combination Well Tolerated in Several Lymphomas

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

In Brief: NCI Contract Plans Shaping Up As RFP “Season” Approaches; L-B Profit Told

September 13, 1974

Risk of Relapse Continues After Five Years of Therapy

August 29, 2008

NCI Halts Routine P01 Site Visits Due to Travel Cut

February 7, 1992

Yarbro-Chabner Debate Continues

April 29, 1983

Trials Approved In October

December 28, 2001

Ethics rules slammed by NIH scientists, institute directors, societies, Senators.

April 8, 2005